Market LIVE
Published markets; coverage varies by country
Product profile · United States

XARELTO

 ·  Patent Litigation & Settlement History ↓

IngredientRIVAROXABAN
Application typeNDA
Application022406
Product002
Dosage formTABLET
RouteORAL
Strength15MG
Approval date2011-11-04
Marketing statusPrescription
Status event—
ApplicantJANSSEN PHARMS
Product source

Current GenericRadar decision

Year2025
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2025-05-14
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2025-05-14
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
95392182034-02-17U U-1953———
———
95392182034-02-17U U-3289———
———
95392182034-08-17— ————
—2034-08-17—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
208549 / 002APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——PRINSTON INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208534 / 003FINAL_APPROVAL · FINAL_APPROVED2025-05-14—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208543 / 002FINAL_APPROVAL · FINAL_APPROVED2025-05-14—INVAGEN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208555 / 003FINAL_APPROVAL · FINAL_APPROVED2025-05-14—LUPIN LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210301 / 003FINAL_APPROVAL · FINAL_APPROVED2025-05-14—ALEMBIC PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213114 / 003FINAL_APPROVAL · FINAL_APPROVED2025-05-14—MACLEODS PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213348 / 002FINAL_APPROVAL · FINAL_APPROVED2025-05-14—SUNSHINE LAKE PHARMA CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
216995 / 002FINAL_APPROVAL · FINAL_APPROVED2025-05-14—AIPING PHARMACEUTICAL INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
218107 / 003FINAL_APPROVAL · FINAL_APPROVED2025-05-14—BIOCON PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
219332 / 003FINAL_APPROVAL · FINAL_APPROVED2025-05-14—ASCENT PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208220 / 002FINAL_APPROVAL · FINAL_APPROVED2025-05-15—BRECKENRIDGE PHARMACEUTICAL INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208544 / 003FINAL_APPROVAL · FINAL_APPROVED2025-05-15—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
218117 / 003FINAL_APPROVAL · FINAL_APPROVED2025-07-31—SCIEGEN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
218445 / 003FINAL_APPROVAL · FINAL_APPROVED2025-08-11—REGCON HOLDINGS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208557 / 003FINAL_APPROVAL · FINAL_APPROVED2025-10-07—TARO PHARMACEUTICAL INDUSTRIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208546 / 003FINAL_APPROVAL · FINAL_APPROVED2025-10-24—MSN LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208579 / 002FINAL_APPROVAL · FINAL_APPROVED2025-11-14—APOTEX INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208334 / 003FINAL_APPROVAL · FINAL_APPROVED2026-06-30—MICRO LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
220874 / 003FINAL_APPROVAL · FINAL_APPROVED2026-07-01—MANKIND PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
216255 / 003FINAL_APPROVAL · FINAL_APPROVED2026-08-19—EPIC PHARMA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 19 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
208534 / 003DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2025-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208543 / 002INVAGEN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2025-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208555 / 003LUPIN LTDFINAL_APPROVAL · FINAL_APPROVED2025-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210301 / 003ALEMBIC PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2025-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213114 / 003MACLEODS PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2025-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213348 / 002SUNSHINE LAKE PHARMA CO LTDFINAL_APPROVAL · FINAL_APPROVED2025-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
216995 / 002AIPING PHARMACEUTICAL INCFINAL_APPROVAL · FINAL_APPROVED2025-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
218107 / 003BIOCON PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2025-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
219332 / 003ASCENT PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2025-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208220 / 002BRECKENRIDGE PHARMACEUTICAL INCFINAL_APPROVAL · FINAL_APPROVED2025-05-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208544 / 003AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2025-05-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
218117 / 003SCIEGEN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2025-07-31 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
218445 / 003REGCON HOLDINGS LLCFINAL_APPROVAL · FINAL_APPROVED2025-08-11 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208557 / 003TARO PHARMACEUTICAL INDUSTRIES LTDFINAL_APPROVAL · FINAL_APPROVED2025-10-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208546 / 003MSN LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2025-10-24 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208579 / 002APOTEX INCFINAL_APPROVAL · FINAL_APPROVED2025-11-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208334 / 003MICRO LABS LTDFINAL_APPROVAL · FINAL_APPROVED2026-06-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
220874 / 003MANKIND PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2026-07-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
216255 / 003EPIC PHARMA LLCFINAL_APPROVAL · FINAL_APPROVED2026-08-19 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2025-05-14TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.